Eligibility and Disqualification Recommendations for Competitive Athletes with Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement from the American Heart Association and American College of Cardiology

Circulation

Volumn 132, Issue 22, 2015, Pages e273-e280

  Maron, Barry J ^a   Udelson, James E ^b   Bonow, Robert O ^c   Nishimura, Rick A ^d   Ackerman, Michael J ^d   Estes, N A Mark ^b   Cooper, Leslie T ^d   Link, Mark S ^b   Maron, Martin S ^b  

^a MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d MAYO CLINIC   (United States)

Author keywords

AHA Scientific Statements; arrhythmogenic right ventricular cardiomyopathy; athletes; cardiomyopathy; cardiovascular abnormalities; cardiovascular magnetic resonance; hypertrophic cardiomyopathy; myocarditis; sudden death

Indexed keywords

ATHLETE; CARDIOVASCULAR MALFORMATION; GENOTYPE; HEART RIGHT VENTRICLE DYSPLASIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MYOCARDITIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SPORTS AND SPORT RELATED PHENOMENA; SUDDEN DEATH; VENTRICULAR NONCOMPACTION; ADVISORY COMMITTEE; ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA; CARDIOLOGY; CARDIOMYOPATHIES; CARDIOMYOPATHY, HYPERTROPHIC; CARDIOVASCULAR ABNORMALITIES; MEDICAL SOCIETY; PRACTICE GUIDELINE; PROCEDURES; STANDARDS; UNITED STATES;

ADVISORY COMMITTEES; AMERICAN HEART ASSOCIATION; ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA; ATHLETES; CARDIOLOGY; CARDIOMYOPATHIES; CARDIOMYOPATHY, HYPERTROPHIC; CARDIOVASCULAR ABNORMALITIES; HUMANS; MYOCARDITIS; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 84949324348     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIR.0000000000000239     Document Type: Review

References (64)

1. Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013;381:242-255. doi: 10.1016/S0140-6736(12)60397-3.
2. Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine [published correction appears in J Am Coll Cardiol. 2014;64:1188]. J Am Coll Cardiol. 2014;64:83-99. doi: 10.1016/j.jacc.2014.05.003.
3. Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation. 2009;119:1085-1092. doi: 10.1161/CIRCULATIONAHA.108.804617.
4. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA Study: Coronary Artery Risk Development in (Young) Adults. Circulation. 1995;92:785-789.
5. Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol. 2012;60:705-715. doi: 10.1016/j.jacc.2012.02.068.
6. Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, Olivotto I, Biller L, Lesser JR, Udelson JE, Manning WJ, Appelbaum E. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol. 2009;54:220-228. doi: 10.1016/j. jacc.2009.05.006.
7. Maron BJ, Rowin EJ, Casey SA, Link MS, Lesser JR, Chan RH, Garberich RF, Udelson JE, Maron MS. Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies. J Am Coll Cardiol. 2015;65:1915-1928. doi: 10.1016/j. jacc.2015.02.061.
8. Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes NA 3rd, Favale S, Piccininno M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P. Implantable cardioverterdefibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy [published correction appears in JAMA. 2007;298:1516]. JAMA. 2007;298:405-412. doi: 10.1001/jama.298.4.405.
9. Schinkel AF, Vriesendorp PA, Sijbrands EJ, Jordaens LJ, ten Cate FJ, Michels M. Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis. Circ Heart Fail. 2012;5:552-559. doi: 10.1161/CIRCHEARTFAILURE.112.969626.
10. Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NA 3rd, Shannon KM, Ashley EA, Day SM, Pacileo G, Formisano F, Devoto E, Anastasakis A, Bos JM, Woo A, Autore C, Pass RH, Boriani G, Garberich RF, Almquist AK, Russell MW, Boni L, Berger S, Maron MS, Link MS. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;61:1527-1535. doi: 10.1016/j. jacc.2013.01.037.
11. Maron BJ, Ackerman MJ, Nishimura RA, Pyeritz RE, Towbin JA, Udelson JE. Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis and Marfan syndrome. J Am Coll Cardiol 2005;45:1340-1345.
12. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:2761-2796. doi: 10.1161/CIR.0b013e318223e230.
13. Maron BJ, Yeates L, Semsarian C. Clinical challenges of genotype positive (+)-phenotype negative (-) family members in hypertrophic cardiomyopathy. Am J Cardiol. 2011;107:604-608. doi: 10.1016/j. amjcard.2010.10.022.
14. Maron BJ, Niimura H, Casey SA, Soper MK, Wright GB, Seidman JG, Seidman CE. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. J Am Coll Cardiol. 2001;38:315-321.
15. Maron BJ, Haas TS, Kitner C, Lesser JR. Onset of apical hypertrophic cardiomyopathy in adulthood. Am J Cardiol. 2011;108:1783-1787. doi: 10.1016/j.amjcard.2011.07.048.
16. Ho CY, Sweitzer NK, McDonough B, Maron BJ, Casey SA, Seidman JG, Seidman CE, Solomon SD. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation. 2002;105:2992-2997.
17. Maron MS, Rowin EJ, Lin D, Appelbaum E, Chan RH, Gibson CM, Lesser JR, Lindberg J, Haas TS, Udelson JE, Manning WJ, Maron BJ. Prevalence and clinical profile of myocardial crypts in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2012;5:441-447. doi: 10.1161/CIRCIMAGING.112.972760.
18. Rowin EJ, Maron MS, Lesser JR, Maron BJ. CMR with late gadolinium enhancement in genotype positive-phenotype negative hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. 2012;5:119-122. doi: 10.1016/j.jcmg.2011.08.020.
19. Maron MS, Olivotto I, Harrigan C, Appelbaum E, Gibson CM, Lesser JR, Haas TS, Udelson JE, Manning WJ, Maron BJ. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation. 2011;124:40-47. doi: 10.1161/CIRCULATIONAHA.110.985812.
20. Christiaans I, Lekanne dit Deprez RH, van Langen IM, Wilde AA. Ventricular fibrillation in MYH7-related hypertrophic cardiomyopathy before onset of ventricular hypertrophy. Heart Rhythm. 2009;6:1366-1369. doi: 10.1016/j.hrthm.2009.04.029.
21. Rickers C, Wilke NM, Jerosch-Herold M, Casey SA, Panse P, Panse N, Weil J, Zenovich AG, Maron BJ. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation. 2005;112:855-861. doi: 10.1161/CIRCULATIONAHA.104.507723.
22. Levine BD, Baggish AL, Kovacs RJ, Link MS, Maron MS, Mitchell JH; on behalf of the American Heart Association Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Functional Genomics and Translational Biology, and the American College of Cardiology. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 1: classification of sport: dynamic, static, and impact: a scientific statement from the American Heart Association and American College of Cardiology. Circulation. 2015;132:e262-e266.
23. Zipes DP, Link MS, Ackerman MJ, Kovacs RJ, Myerburg RJ, Estes NAM 3rd; on behalf of the American Heart Association Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Functional Genomics and Translational Biology, and the American College of Cardiology. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 9: arrhythmias and conduction defects: a scientific statement from the American Heart Association and American College of Cardiology. Circulation. 2015;132:e315-e325.
24. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113:1807-1816. doi: 10.1161/CIRCULATIONAHA.106.174287.
25. Stacey RB, Andersen M, Haag J, Hall ME, McLeod G, Upadhya B, Hundley WG, Thohan V. Right ventricular morphology and systolic function in left ventricular noncompaction cardiomyopathy. Am J Cardiol. 2014;113:1018-1023. doi: 10.1016/j.amjcard.2013.12.008.
26. Oechslin EN, Attenhofer Jost CH, Rojas JR, Kaufmann PA, Jenni R. Long-term follow-up of 34 adults with isolated left ventricular noncompaction: a distinct cardiomyopathy with poor prognosis. J Am Coll Cardiol. 2000;36:493-500.
27. Klaassen S, Probst S, Oechslin E, Gerull B, Krings G, Schuler P, Greutmann M, Hürlimann D, Yegitbasi M, Pons L, Gramlich M, Drenckhahn JD, Heuser A, Berger F, Jenni R, Thierfelder L. Mutations in sarcomere protein genes in left ventricular noncompaction. Circulation. 2008;117:2893-2901. doi: 10.1161/CIRCULATIONAHA.107.746164.
28. Gati S, Chandra N, Bennett RL, Reed M, Kervio G, Panoulas VF, Ghani S, Sheikh N, Zaidi A, Wilson M, Wilson M, Papadakis M, Carré F, Sharma S. Increased left ventricular trabeculation in highly trained athletes: do we need more stringent criteria for the diagnosis of left ventricular non-compaction in athletes [published correction appears in Heart. 2013;99:506]? Heart. 2013;99:401-408. doi: 10.1136/heartjnl-2012-303418.
29. Ganga HV, Thompson PD. Sports participation in non-compaction cardiomyopathy: a systematic review. Br J Sports Med. 2014;48:1466-1471. doi: 10.1136/bjsports-2012-091855.
30. Thavendiranathan P, Dahiya A, Phelan D, Desai MY, Tang WH. Isolated left ventricular non-compaction controversies in diagnostic criteria, adverse outcomes and management. Heart. 2013;99:681-689. doi: 10.1136/heartjnl-2012-302816.
31. Caliskan K, Michels M, Geleijnse ML, van Domburg RT, van der Boon R, Balk AH, Simoons ML. Frequency of asymptomatic disease among family members with noncompaction cardiomyopathy. Am J Cardiol. 2012;110:1512-1517. doi: 10.1016/j.amjcard.2012.07.009.
32. Kelley-Hedgepeth A, Towbin JA, Maron MS. Images in cardiovascular medicine: overlapping phenotypes: left ventricular noncompaction and hypertrophic cardiomyopathy. Circulation. 2009;119:e588-e589. doi: 10.1161/CIRCULATIONAHA.108.829564.
33. Greutmann M, Mah ML, Silversides CK, Klaassen S, Attenhofer Jost CH, Jenni R, Oechslin EN. Predictors of adverse outcome in adolescents and adults with isolated left ventricular noncompaction. Am J Cardiol. 2012;109:276-281. doi: 10.1016/j.amjcard.2011.08.043.
34. Brescia ST, Rossano JW, Pignatelli R, Jefferies JL, Price JF, Decker JA, Denfield SW, Dreyer WJ, Smith O, Towbin JA, Kim JJ. Mortality and sudden death in pediatric left ventricular noncompaction in a tertiary referral center. Circulation. 2013;127:2202-2208. doi: 10.1161/CIRCULATIONAHA.113.002511.
35. Paterick TE, Tajik AJ. Left ventricular noncompaction: a diagnostically challenging cardiomyopathy. Circ J. 2012;76:1556-1562.
36. Jenni R, Oechslin E, Schneider J, Attenhofer Jost C, Kaufmann PA. Echocardiographic and pathoanatomical characteristics of isolated left ventricular non-compaction: a step towards classification as a distinct cardiomyopathy. Heart. 2001;86:666-671.
37. Pelliccia A, Culasso F, Di Paolo FM, Maron BJ. Physiologic left ventricular cavity dilatation in elite athletes. Ann Intern Med. 1999;130:23-31.
38. Pelliccia A, Maron BJ, Culasso F, Spataro A, Caselli G. Athlete's heart in women: echocardiographic characterization of highly trained elite female athletes. JAMA. 1996;276:211-215.
39. Karjalainen J, Heikkilä J. Incidence of three presentations of acute myocarditis in young men in military service: a 20-year experience. Eur Heart J. 1999;20:1120-1125. doi: 10.1053/euhj.1998.1444.
40. Weber MA, Ashworth MT, Risdon RA, Malone M, Burch M, Sebire NJ. Clinicopathological features of paediatric deaths due to myocarditis: an autopsy series. Arch Dis Child. 2008;93:594-598. doi: 10.1136/adc.2007.128686.
41. Morentin B, Suárez-Mier MP, Aguilera B, Bodegas A. Myocardial disease mortality in children and young adults: a population-based observational study [in Spanish]. Rev Esp Cardiol. 2006;59:238-246.
42. Kitulwatte ID, Kim PJ, Pollanen MS. Sudden death related myocarditis: a study of 56 cases. Forensic Sci Med Pathol. 2010;6:13-19. doi: 10.1007/s12024-009-9125-5.
43. Corrado D, Basso C, Thiene G. Sudden cardiac death in young people with apparently normal heart. Cardiovasc Res. 2001;50:399-408.
44. Phillips M, Robinowitz M, Higgins JR, Boran KJ, Reed T, Virmani R. Sudden cardiac death in Air Force recruits: a 20-year review. JAMA. 1986;256:2696-2699.
45. Kiel RJ, Smith FE, Chason J, Khatib R, Reyes MP. Coxsackievirus B3 myocarditis in C3H/HeJ mice: description of an inbred model and the effect of exercise on virulence. Eur J Epidemiol. 1989;5:348-350.
46. Hosenpud JD, Campbell SM, Niles NR, Lee J, Mendelson D, Hart MV. Exercise induced augmentation of cellular and humoral autoimmunity associated with increased cardiac dilatation in experimental autoimmune myocarditis. Cardiovasc Res. 1987;21:217-222.
47. Machado S, Roubille F, Gahide G, Vernhet-Kovacsik H, Cornillet L, Cung TT, Sportouch-Dukhan C, Raczka F, Pasquié JL, Gervasoni R, Macia JC, Cransac F, Davy JM, Piot C, Leclercq F. Can troponin elevation predict worse prognosis in patients with acute pericarditis? Ann Cardiol Angeiol (Paris). 2010;59:1-7. doi: 10.1016/j.ancard.2009.07.009.
48. Imazio M, Cooper LT. Management of myopericarditis. Expert Rev Cardiovasc Ther. 2013;11:193-201. doi: 10.1586/erc.12.184.
49. Imazio M, Brucato A, Barbieri A, Ferroni F, Maestroni S, Ligabue G, Chinaglia A, Cumetti D, Della Casa G, Bonomi F, Mantovani F, Di Corato P, Lugli R, Faletti R, Leuzzi S, Bonamini R, Modena MG, Belli R. Good prognosis for pericarditis with and without myocardial involvement: results from a multicenter, prospective cohort study. Circulation. 2013;128:42-49. doi: 10.1161/CIRCULATIONAHA.113.001531.
50. Cooper LT Jr. Myocarditis. N Engl J Med. 2009;360:1526-1538. doi: 10.1056/NEJMra0800028.
51. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, White JA, Abdel-Aty H, Gutberlet M, Prasad S, Aletras A, Laissy JP, Paterson I, Filipchuk NG, Kumar A, Pauschinger M, Liu P; International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis. Cardiovascular magnetic resonance in myocarditis: a JACC White Paper. J Am Coll Cardiol. 2009;53:1475-1487. doi: 10.1016/j. jacc.2009.02.007.
52. Grün S, Schumm J, Greulich S, Wagner A, Schneider S, Bruder O, Kispert EM, Hill S, Ong P, Klingel K, Kandolf R, Sechtem U, Mahrholdt H. Longterm follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol. 2012;59:1604-1615. doi: 10.1016/j.jacc.2012.01.007.
53. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, Levine GN, Narula J, Starling RC, Towbin J, Virmani R. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation. 2007;116:2216-2233. doi: 10.1161/CIRCULATIONAHA.107.186093.
54. Corrado D, Basso C, Pavei A, Michieli P, Schiavon M, Thiene G. Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program. JAMA. 2006;296:1593-1601. doi: 10.1001/jama.296.13.1593.
55. Basso C, Corrado D, Marcus FI, Nava A, Thiene G. Arrhythmogenic right ventricular cardiomyopathy. Lancet. 2009;373:1289-1300. doi: 10.1016/S0140-6736(09)60256-7.
56. Corrado D, Thiene G. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: clinical impact of molecular genetic studies. Circulation. 2006;113:1634-1637. doi: 10.1161/CIRCULATIONAHA.105.616490.
57. Sen-Chowdhry S, Syrris P, McKenna WJ. Role of genetic analysis in the management of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2007;50:1813-1821. doi: 10.1016/j. jacc.2007.08.008.
58. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, Calkins H, Corrado D, Cox MG, Daubert JP, Fontaine G, Gear K, Hauer R, Nava A, Picard MH, Protonotarios N, Saffitz JE, Sanborn DM, Steinberg JS, Tandri H, Thiene G, Towbin JA, Tsatsopoulou A, Wichter T, Zareba W. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J. 2010;31:806-814. doi: 10.1093/eurheartj/ehq025.
59. Kirchhof P, Fabritz L, Zwiener M, Witt H, Schäfers M, Zellerhoff S, Paul M, Athai T, Hiller KH, Baba HA, Breithardt G, Ruiz P, Wichter T, Levkau B. Age-and training-dependent development of arrhythmogenic right ventricular cardiomyopathy in heterozygous plakoglobin-deficient mice. Circulation. 2006;114:1799-1806. doi: 10.1161/CIRCULATIONAHA.106.624502.
60. James CA, Bhonsale A, Tichnell C, Murray B, Russell SD, Tandri H, Tedford RJ, Judge DP, Calkins H. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol. 2013;62:1290-1297. doi: 10.1016/j.jacc.2013.06.033.
61. Thiene G, Nava A, Corrado D, Rossi L, Pennelli N. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med. 1988;318:129-133. doi: 10.1056/NEJM198801213180301.
62. Corrado D, Leoni L, Link MS, Della Bella P, Gaita F, Curnis A, Salerno JU, Igidbashian D, Raviele A, Disertori M, Zanotto G, Verlato R, Vergara G, Delise P, Turrini P, Basso C, Naccarella F, Maddalena F, Estes NA 3rd, Buja G, Thiene G. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation. 2003;108:3084-3091. doi: 10.1161/01.CIR.0000103130.33451.D2.
63. Wichter T, Paul M, Wollmann C, Acil T, Gerdes P, Ashraf O, Tjan TD, Soeparwata R, Block M, Borggrefe M, Scheld HH, Breithardt G, Böcker D. Implantable cardioverter/defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy: single-center experience of long-term followup and complications in 60 patients. Circulation. 2004;109:1503-1508. doi: 10.1161/01.CIR.0000121738.88273.43.
64. Corrado D, Calkins H, Link MS, Leoni L, Favale S, Bevilacqua M, Basso C, Ward D, Boriani G, Ricci R, Piccini JP, Dalal D, Santini M, Buja G, Iliceto S, Estes NA 3rd, Wichter T, McKenna WJ, Thiene G, Marcus FI. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. Circulation. 2010;122:1144-1152. doi: 10.1161/CIRCULATIONAHA.109.913871.